Baudax Bio Corporate Controller resigns; appoints Interim CFO via Danforth

Baudax Bio, Inc.

Jillian Dilmore resigns as Corporate Controller, PFO, PAO, and Corporate Secretary effective Oct 9, 2023; she will provide continued consulting support.
Board appoints Natalie McAndrew as Interim CFO effective Oct 9, 2023; she will also serve as PFO and PAO through Danforth Advisors.
McAndrew, age 49, is a Director at Danforth Advisors, a life science advisory firm; no family relationships with executives.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jillian Dilmore

Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary

Baudax Bio, Inc.

Effective: 2023-10-09
Successor: Natalie McAndrew
Filed: October 6, 2023, 7:59 PM ET

On October 2, 2023, Jillian Dilmore, the Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Baudax Bio, Inc. (the “Company”) notified the Company of her decision to resign effective as of October 9, 2023 (the “Effective Date”).

Appointed (interim)

Natalie McAndrew

Interim Chief Financial Officer

Baudax Bio, Inc.

Effective: 2023-10-09
Filed: October 6, 2023, 7:59 PM ET

On October 5, 2023, the board of directors of the Company appointed Natalie McAndrew as Interim Chief Financial Officer, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jillian Dilmore resigned as Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary at Baudax Bio, Inc..

Action: resigned
Role: Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary

Exact text from the filing

On October 2, 2023, Jillian Dilmore, the Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Baudax Bio, Inc. (the “Company”) notified the Company of her decision to resign effective as of October 9, 2023 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Natalie McAndrew was appointed as Interim Chief Financial Officer at Baudax Bio, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On October 5, 2023, the board of directors of the Company appointed Natalie McAndrew as Interim Chief Financial Officer, effective as of the Effective Date.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-23-251966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.